Tokyo Tape
Sign in
← I'rom Group

Quarterly report · Q2

2372.TEDINET S100S4U1
Period2023-04-01 → 2023-09-30
Filed2023-11-07
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 48
MetricValuePeriodScopeSource row
Revenue¥8.7bn2023-04-01 → 2023-09-30Cons.Net sales
Revenue¥18.4bn2022-04-01 → 2023-03-31Cons.Net sales (5-year summary)
Revenue¥9.6bn2022-04-01 → 2022-09-30Cons.Net sales
Operating income¥790m2023-04-01 → 2023-09-30Cons.Operating income
Operating income¥2.4bn2022-04-01 → 2022-09-30Cons.Operating income
Ordinary income¥1.2bn2023-04-01 → 2023-09-30Cons.Ordinary income
Ordinary income¥3.3bn2022-04-01 → 2023-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥2.5bn2022-04-01 → 2022-09-30Cons.Ordinary income
Profit before tax¥1.4bn2023-04-01 → 2023-09-30Cons.Income before income taxes
Profit before tax¥2.6bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Net income (owners)¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.5bn2022-04-01 → 2023-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.1bn2023-04-01 → 2023-09-30Cons.Profit loss
Net income¥2.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Total assets¥36.2bnat 2023-09-30Cons.Assets
Total assets¥35.1bnat 2023-03-31Cons.Assets
Total assets¥30.4bnat 2022-09-30Cons.Total assets (5-year summary)
Total liabilities¥23.3bnat 2023-09-30Cons.Liabilities
Total liabilities¥23.0bnat 2023-03-31Cons.Liabilities
Net assets / equity¥13.0bnat 2023-09-30Cons.Net assets
Net assets / equity¥12.2bnat 2023-03-31Cons.Net assets
Net assets / equity¥12.0bnat 2022-09-30Cons.Net assets (5-year summary)
Cash and deposits¥8.9bnat 2023-09-30Cons.Cash and deposits
Cash and deposits¥9.4bnat 2023-03-31Cons.Cash and deposits
Cash & equivalents¥8.9bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥9.4bnat 2023-03-31Cons.Cash and cash equivalents
Cash & equivalents¥7.0bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥6.4bnat 2022-03-31dCons.Cash and cash equivalents
Operating cash flow¥803m2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥3.6bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥2.5bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.3bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.8bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥2.7bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Financing cash flow¥17m2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥4.3bn2022-04-01 → 2023-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥740m2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥90.222023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥16.562023-07-01 → 2023-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥210.222022-04-01 → 2023-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥164.172022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥75.82022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥210.062022-04-01 → 2023-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥163.912022-04-01 → 2022-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio35.7%at 2023-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio34.6%at 2023-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio39.2%at 2022-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 62
SegmentItemPeriodValue
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2023-04-01 → 2023-09-30¥250m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2023-04-01 → 2023-09-30¥219m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2023-04-01 → 2023-09-30¥31m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2023-04-01 → 2023-09-30−¥542m
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥764m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2023-04-01 → 2023-09-30¥1.7bn
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥844m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥885m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2023-04-01 → 2023-09-30−¥23m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2023-04-01 → 2023-09-30¥3.4bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2023-04-01 → 2023-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥610m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2023-04-01 → 2023-09-30¥66m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2023-04-01 → 2023-09-30¥943m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2023-04-01 → 2023-09-30¥533m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥409m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2023-04-01 → 2023-09-30−¥35m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2023-04-01 → 2023-09-30¥4.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥490m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.1bn
—segment totalrevenue2023-04-01 → 2023-09-30¥10.9bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥8.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.1bn
Total Of Reportable Segments And Otherssegment totalrevenue2023-04-01 → 2023-09-30¥11.1bn
Total Of Reportable Segments And Otherssegment totalrevenue external2023-04-01 → 2023-09-30¥8.7bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2023-04-01 → 2023-09-30¥2.4bn
Total Of Reportable Segments And Otherssegment totalsegment profit2023-04-01 → 2023-09-30¥1.6bn
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue2022-04-01 → 2022-09-30¥68m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue external2022-04-01 → 2022-09-30¥28m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentsrevenue intersegment2022-04-01 → 2022-09-30¥39m
Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segmentssegment profit2022-04-01 → 2022-09-30−¥118m
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-09-30−¥641m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30−¥673m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue2022-04-01 → 2022-09-30¥594m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue external2022-04-01 → 2022-09-30¥592m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥1m
jpcrp040300-q2r_E05352-000Advanced Medicalreportable segmentsegment profit2022-04-01 → 2022-09-30−¥184m
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue2022-04-01 → 2022-09-30¥2.8bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue external2022-04-01 → 2022-09-30¥2.7bn
jpcrp040300-q2r_E05352-000CROreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥88m
jpcrp040300-q2r_E05352-000CROreportable segmentsegment profit2022-04-01 → 2022-09-30¥82m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue2022-04-01 → 2022-09-30¥978m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue external2022-04-01 → 2022-09-30¥528m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥449m
jpcrp040300-q2r_E05352-000Medical Supportreportable segmentsegment profit2022-04-01 → 2022-09-30¥28m
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue2022-04-01 → 2022-09-30¥5.8bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue external2022-04-01 → 2022-09-30¥5.7bn
jpcrp040300-q2r_E05352-000SMOreportable segmentrevenue intersegment2022-04-01 → 2022-09-30¥61m
jpcrp040300-q2r_E05352-000SMOreportable segmentsegment profit2022-04-01 → 2022-09-30¥3.3bn
—segment totalrevenue2022-04-01 → 2022-09-30¥10.2bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
—segment totalrevenue intersegment2022-04-01 → 2022-09-30¥601m
—segment totalsegment profit2022-04-01 → 2022-09-30¥3.2bn
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥10.3bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥9.6bn
Total Of Reportable Segments And Otherssegment totalrevenue intersegment2022-04-01 → 2022-09-30¥641m
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥3.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 540
ItemContextValueUnit
Cost of salesPrior1YTDDuration4613000000JPY
Cost of salesCurrentYTDDuration4862000000JPY
Gross profitPrior1YTDDuration5026000000JPY
Gross profitCurrentYTDDuration3816000000JPY
Directors compensations sgaPrior1YTDDuration241000000JPY
Directors compensations sgaCurrentYTDDuration253000000JPY
Salaries allowances and bonuses sgaPrior1YTDDuration1019000000JPY
Salaries allowances and bonuses sgaCurrentYTDDuration1214000000JPY
Commission fee sgaPrior1YTDDuration89000000JPY
Commission fee sgaCurrentYTDDuration116000000JPY
Rent expenses sgaPrior1YTDDuration202000000JPY
Rent expenses sgaCurrentYTDDuration241000000JPY
Research and development expenses sgaPrior1YTDDuration371000000JPY
Research and development expenses sgaCurrentYTDDuration242000000JPY
Other sgaPrior1YTDDuration692000000JPY
Other sgaCurrentYTDDuration957000000JPY
Selling general and administrative expensesPrior1YTDDuration2616000000JPY
Selling general and administrative expensesCurrentYTDDuration3025000000JPY
Operating incomePrior1YTDDuration2409000000JPY
Operating incomeCurrentYTDDuration790000000JPY
Interest income noiPrior1YTDDuration4000000JPY
Interest income noiCurrentYTDDuration8000000JPY
Dividends income noiPrior1YTDDuration0JPY
Dividends income noiCurrentYTDDuration0JPY
Foreign exchange gains noiPrior1YTDDuration349000000JPY
Foreign exchange gains noiCurrentYTDDuration511000000JPY
Subsidy income noi bountyPrior1YTDDuration55000000JPY
Subsidy income noi bountyCurrentYTDDuration43000000JPY
Land and house rent received noiPrior1YTDDuration2000000JPY
Land and house rent received noiCurrentYTDDuration107000000JPY
Other noiPrior1YTDDuration53000000JPY
Other noiCurrentYTDDuration25000000JPY
Non operating incomePrior1YTDDuration465000000JPY
Non operating incomeCurrentYTDDuration697000000JPY
Interest expenses noePrior1YTDDuration64000000JPY
Interest expenses noeCurrentYTDDuration85000000JPY
Loss on investment of securities noePrior1YTDDuration181000000JPY
Loss on investment of securities noeCurrentYTDDuration56000000JPY
Commission fee noePrior1YTDDuration124000000JPY
Commission fee noeCurrentYTDDuration7000000JPY
Cost of lease revenue noePrior1YTDDuration0JPY
Cost of lease revenue noeCurrentYTDDuration91000000JPY
Other noePrior1YTDDuration0JPY
Other noeCurrentYTDDuration21000000JPY
Non operating expensesPrior1YTDDuration372000000JPY
Non operating expensesCurrentYTDDuration263000000JPY
Ordinary incomePrior1YTDDuration2503000000JPY
Ordinary incomeCurrentYTDDuration1225000000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration59000000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration193000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2023-03-31pass rounding
balance sheet identityconsolidated 2023-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2023-03-31pass
statement vs summary · net assetsconsolidated 2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · total assetsconsolidated 2023-03-31pass
statement vs summary · total assetsconsolidated 2023-09-30pass